Bionomics (BNO) is an Australian biopharmaceutical company specialising in ion channel drug discovery for central nervous system (CNS) disorders such as anxiety, post-traumatic stress disorder (PTSD) and Alzheimer’s disease, and in oncology. In addition to developing four proprietary drug candidates, BNO offers contract and partnered drug discovery based on its proprietary technology platforms: MultiCore and ionX. The sales model includes fees-for-service, licensing income, and royalties from successful partnered products. BNO is in a growth phase, with its strategic focus on commercialising BNC210, its lead CNS drug candidate in PTSD.
If you'd like to be introduced to the team at Bionomics Ltd, get in touch.Request a meeting